Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02644122 · ClinicalTrials.gov registry record · Phase 2
SF1126 in Recurrent or Progressive SCCHN and Mutations in PIK3CA Gene and/or PI-3 Kinase Pathway Genes
A Phase 2 study, sponsored by Ezra Cohen.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT02644122 is a Phase 2 study that was terminated before completion, run by Ezra Cohen. The registered enrollment target is 1 participants.
The verdict
NCT02644122, a Phase 2 study, was terminated before completion, sponsored by Ezra Cohen.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
The purpose of this study is to test the good and bad effects of an experimental drug called SF1126. This drug is being tested in patients whose cancer has not been controlled by available standard therapies and who have certain genes in their tumor. SF1126 is a drug that inhibits a cell protein called phosphatidyl inositol 3 kinase (PI3K). PI3K is part of signaling pathway that tells cancer cells to grow, survive, invade and metastasize. PI3K also has an important role in the development of blood vessels that are required to support tumor growth. SF1126 is being developed by SignalRx Pharmaceuticals, Inc. It is considered an experimental drug because it is not approved by the FDA for any disease treatment.
Interventions
- DRUG SF1126
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2016-11 |
| Est. Completion | 2016-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02644122
The ClinicalTrials.gov registry entry for NCT02644122 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ezra Cohen, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SF1126 is the first listed.
NCT02644122 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02644122 about?
NCT02644122 is a clinical study titled "SF1126 in Recurrent or Progressive SCCHN and Mutations in PIK3CA Gene and/or PI-3 Kinase Pathway Genes". The purpose of this study is to test the good and bad effects of an experimental drug called SF1126. This drug is being tested in patients whose cancer has not been controlled by available standard therapies and who have certain genes in their tumor. SF1126 is a drug that inhibits a cell protein ca...
What is the current status of trial NCT02644122?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2016-11. Estimated completion is 2016-12.
What interventions are being tested in trial NCT02644122?
The interventions under investigation include: SF1126 (DRUG).
Who is sponsoring clinical trial NCT02644122?
This trial is sponsored by Ezra Cohen, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.